Full Title
Open Access Protocol of targeted radiotherapy with 131I-metaiodobenzylguanidine (131I-MIBG) in patients with resistant neuroblastoma or malignant chromaffin cell tumorsPurpose
Metaiodobenzylguanidine (MIBG) is a substance taken up specifically by neuroblastoma, pheochromocytoma, or paraganglioma tumor cells. MIBG can be combined with radioactive iodine (<sup>131</sup>I) in the laboratory to form the radioactive compound <sup>131</sup>I-MIBG. The <sup>131</sup>I-MIBG compound concentrates more in cancer cells than in normal cells. It may therefore deliver more radiation directly to cancer cells while sparing normal organs.
The purpose of this research study is to assess the safety and effectiveness of <sup>131</sup>I-MIBG in patients with neuroblastoma, malignant pheochromocytoma, or malignant paraganglioma that came back or keeps growing despite standard treatments.
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a diagnosis of neuroblastoma, malignant pheochromocytoma, or malignant paraganglioma that came back or keeps growing despite standard treatments.
- At least 2 weeks must have passed since prior biological therapy and 3 weeks since prior chemotherapy and entry into the study.
- Patients must be older than 1 year of age.
Contact
For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.